Etanercept: a clinical review of current and emerging indications. - Wikidata - awgldk - TriplyDB

Etanercept: a clinical review of current and emerging indications.

Etanercept: a clinical review of current and emerging indications.

http://www.wikidata.org/entity/Q35779227

about

Utilizing combinatorial engineering to develop Tie2 targeting antagonistic angiopoetin-2 ligands as candidates for anti-angiogenesis therapy Pharmacologic modulation of niche accessibility via tyrosine kinase inhibition enhances marrow and thymic engraftment after hematopoietic stem cell transplantation.Targeting the TNF-alpha pathway in sarcoidosis.Etanercept, a widely used inhibitor of tumor necrosis factor-α (TNF-α), prevents retinal ganglion cell loss in a rat model of glaucoma.Protective effect of etanercept, an inhibitor of tumor necrosis factor-α, in a rat model of retinal ischemia.Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein.TGF-beta inhibitors for the treatment of cancer.Biological therapies for rheumatoid arthritis: progress to date.[A case of recurrent breast cancer with life-threatening multiple lung metastasis markedly responding to CMF as third-line chemotherapy].Engineered ligand-based VEGFR antagonists with increased receptor binding affinity more effectively inhibit angiogenesis.

P2860

Q33779567-CB939A61-9521-466B-A1CE-7A1C314A628A Q33871518-11278032-FFAC-4755-AADA-269094156648 Q34087381-B8BFFE02-0B8A-4E67-BA80-C8788259A914 Q34339649-36CC6839-2163-4450-B6C7-4F8D8965A375 Q36040527-34D5BA5A-99A4-407D-B0CA-0C3F338C7BC8 Q36098699-EA56D703-2B12-4F75-A0EB-675D491C866D Q36187040-D7BDD269-ABDB-41FA-85D8-4A12336B56EB Q38096206-661E9697-FDBC-4677-BF98-FC9720B132BD Q46986955-FA5D6F4A-5B03-408E-9D1D-E76F38726D7C Q50870947-19373E5E-28F8-4AF5-A466-AC9EC797EEE3

P2860

Etanercept: a clinical review of current and emerging indications.

http://www.wikidata.org/entity/Q35779227

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Etanercept: a clinical review of current and emerging indications.

@ast

Etanercept: a clinical review of current and emerging indications.

@en

type

label

Etanercept: a clinical review of current and emerging indications.

@ast

Etanercept: a clinical review of current and emerging indications.

@en

prefLabel

Etanercept: a clinical review of current and emerging indications.

@ast

Etanercept: a clinical review of current and emerging indications.

@en

P1433

Q35779227-B28E00CD-C6C1-4554-BDF9-E14758C0C0CF

P1476

Q35779227-3801A28F-CE37-4729-AE4D-7F18679C8E56

P2093

Q35779227-67219574-ACD7-4C0E-AD7A-F59002012FF8

Q35779227-C95BFB40-79A7-413D-B0BE-7A05F6A8EB00

P2860

Q35779227-247BA99E-C638-41E2-A002-84DDFB747E59

Q35779227-2C9A6C6A-B117-4415-9F12-FE1DC17FB4A8

Q35779227-40241D24-7C70-4194-BAAC-905A6F3D137D

Q35779227-6A5D4C36-A1DC-4EEB-BCE6-C2BA2F703AC2

Q35779227-8C79F47D-0F66-4884-A4E3-76B9CEDD1296

Q35779227-A4D43171-BF54-46D8-BD99-46AB4938D273

Q35779227-A52F4EAB-ADCB-40E5-A07D-3EDD88AEBD57

Q35779227-A96E03E7-FDA4-42CA-89BC-810E3E985C36

Q35779227-BFBC4428-F265-404B-8D60-5F98D7E2F5DA

Q35779227-DA8927C5-FF85-4416-82F1-807833912071

P304

Q35779227-7E50590F-BBE8-41C5-82CD-C137F386BAF3

P31

Q35779227-2E6F940D-850C-4122-A1A7-176D1F7E34D0

P356

Q35779227-04E04A49-CFE0-413E-A07D-BA01EFADD2F7

P407

Q35779227-80D5D29B-3E79-41EF-9208-1913C0CA3300

P433

Q35779227-AF44DAFD-117E-478F-AFD6-017EBCF4CE34

P478

Q35779227-CC42D983-2CB7-4799-B7FA-58795002D2F6

P577

Q35779227-3B0399D5-4125-448C-A5C1-A7D14066CAAB

P698

Q35779227-5982A3A6-D320-4223-AE5D-FB371132FFC5

P356

14656566.5.5.1175

P1433

Expert Opinion on Pharmacotherapy

P1476

Etanercept: a clinical review of current and emerging indications.

@en

P2093

Joan M Bathon

http://www.w3.org/2001/XMLSchema#string

Shikha Nanda

http://www.w3.org/2001/XMLSchema#string

P2860

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept.

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.

Inflammatory bowel disease: new insights into pathogenesis and treatment.

Etanercept in psoriatic arthritis.

The tumor necrosis factor ligand and receptor families.

Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy.

Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety.

Etanercept therapy in children with treatment-resistant uveitis.

P304

1175-1186

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.5.5.1175

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2004-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15155116

http://www.w3.org/2001/XMLSchema#string